• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Omega Therapeutics Inc.

    2/14/22 7:01:52 AM ET
    $OMGA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $OMGA alert in real time by email
    SC 13G 1 d300429dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Schedule 13G

    Under the Securities Exchange Act of 1934

    (Amendment No.     )*

     

     

    Omega Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    68217N105

    (CUSIP Number)

    December 31, 2021

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act (however, see the Notes).

     

     

     


    CUSIP No. 68217N105  

     

      1    

      NAMES OF REPORTING PERSONS

     

      HarbourVest Partners L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      2,647,059

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      2,647,059

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,647,059

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      5.5%(1)

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IA

     

    (1)

    All percentages calculated in this Schedule 13G are based upon an aggregate of 47,774,939 shares of common stock outstanding as reported in Omega Therapeutics, Inc.’s (the “Issuer”) Quarterly Report on Form 10-Q as filed with the Securities and Exchange Commission (the “Commission”) on November 10, 2021.


    CUSIP No. 68217N105  

     

      1    

      NAMES OF REPORTING PERSONS

     

      HarbourVest Partners, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      2,647,059

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      2,647,059

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,647,059

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      5.5%(1)

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IA

     

    (1)

    All percentages calculated in this Schedule 13G are based upon an aggregate of 47,774,939 shares of common stock outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 10, 2021.


    CUSIP: 68217N105  

     

      1    

      NAMES OF REPORTING PERSONS

     

      SMRS-TOPE LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      2,647,059

       6  

      SHARED VOTING POWER

     

      0

       7  

      SOLE DISPOSITIVE POWER

     

      2,647,059

       8  

      SHARED DISPOSITIVE POWER

     

      0

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,647,059

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      5.5%(1)

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO

     

    (1)

    All percentages calculated in this Schedule 13G are based upon an aggregate of 47,774,939 shares of common stock outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 10, 2021.


    CUSIP No. 68217N105  

     

      1    

      NAMES OF REPORTING PERSONS

     

      HVST-TOPE LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      2,647,059

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      2,647,059

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,647,059

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      5.5%(1)

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO

     

    (1)

    All percentages calculated in this Schedule 13G are based upon an aggregate of 47,774,939 shares of common stock outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 10, 2021.


    Item 1.

    (a)    Name of Issuer:

    Omega Therapeutics, Inc. (the “Issuer”)

    (b)    Address of Issuer’s Principal Executive Offices:

    20 Acorn Park Drive

    Cambridge, MA 02140

    (617) 949-4360

    Item 2.

    (a)    Name of Person Filing:

    HarbourVest Partners, LLC

    HarbourVest Partners L.P.

    HVST-TOPE LLC

    SMRS-TOPE LLC

    SMRS-TOPE LLC, HVST-TOPE LLC, HarbourVest Partners L.P. and HarbourVest Partners, LLC have entered into a Joint Filing Agreement, dated February 14, 2022, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which such reporting persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

    (b)    Address of Principal Business Office or, if none, Residence

    The principal business office of each reporting person is One Financial Center, 44th Floor, Boston, MA 02111.

    (c)    Citizenship:

    Reporting entities are all organized and exist under the laws of the State of Delaware.

    (d)    Title of Class of Securities:

    Common stock, par value $0.001 per share (the “Common Stock”)

    (e)    CUSIP Number:

    68217N105

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

    (a)    ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

    (b)    ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

    (c)    ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);


    (d)    ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

    (e)    ☐ An investment adviser in accordance with §240.13d-1(b) (1)(ii)(E);

    (f)    ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b) (1)(ii)(F);

    (g)    ☐ A parent holding company or control person in accordance with §240.13d-1(b) (1)(ii)(G);

    (h)    ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (i)    ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

    (j)    ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

    (k)    ☐ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

    Not Applicable.

     

    Item 4.

    Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a)    Amount beneficially owned:

    Consists of 2,647,059 shares of Common Stock owned directly by SMRS-TOPE LLC.

    HarbourVest Partners, LLC (“HarbourVest”) is the general partner of HarbourVest Partners L.P., which is the manager of HVST-TOPE LLC, which is the managing member of SMRS-TOPE LLC. Each of HarbourVest, HarbourVest Partners L.P. and HVST-TOPE LLC may be deemed to have a beneficial interest in the shares held by SMRS-TOPE LLC.

    Voting and investment power over the securities owned directly by SMRS-TOPE LLC is exercised by the Investment Committee of HarbourVest. Each of HarbourVest, HarbourVest Partners L.P. and HVST-TOPE LLC and the members of the HarbourVest Investment Committee disclaim beneficial ownership of the shares held directly by SMRS-TOPE LLC.

    (b)    Percent of class:

    5.5% (based on 47,774,939 shares of Common Stock outstanding, as reported in the Issuer’s Quarterly Report on Form 10-Q, filed with the SEC on November 10, 2021).

    (c)    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote:

    SMRS-TOPE LLC has the sole power to vote or to direct the vote of 2,647,059 shares of Common Stock.


      (ii)

    Shared power to vote or to direct the vote:

    HarbourVest, HarbourVest Partners L.P. and HVST-TOPE LLC may be deemed to have shared power to vote or direct the vote of 2,647,059 shares of Common Stock. Each of HarbourVest, HarbourVest Partners L.P. and HVST-TOPE LLC disclaim such beneficial ownership of such shares.

     

      (iii)

    Sole power to dispose or to direct the disposition of:

    SMRS-TOPE LLC has the sole power to dispose or to direct the disposition of 2,647,059 shares of Common Stock.

     

      (iv)

    Shared power to dispose or to direct the disposition of:

    HarbourVest, HarbourVest Partners L.P. and HVST-TOPE LLC may be deemed to have shared power to dispose or direct the disposition of 2,647,059 shares of Common Stock. Each of HarbourVest, HarbourVest Partners L.P. and HVST-TOPE LLC disclaim such beneficial ownership of such shares.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    Not Applicable.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not Applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not Applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not Applicable.

     

    Item 10.

    Certification.

    Not Applicable.


    Exhibit Index

     

    Exhibit 1    Agreement of Joint Filing as required by Rule 13d-1(k)(1) under the Exchange Act.


    Signatures

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 14, 2022

     

    HARBOURVEST PARTNERS, LLC
    By:  

    /s/ Paula Drake

    Name:   Paula Drake
    Title:   Chief Compliance Officer, Managing Director and General Counsel
    HARBOURVEST PARTNERS L.P.
    By:   HarbourVest Partners, LLC, its General Partner
    By:  

    /s/ Paula Drake

    Name:   Paula Drake
    Title:   Chief Compliance Officer, Managing Director and General Counsel
    HVST-TOPE LLC
    By:   HarbourVest Partners L.P., its Manager
    By:   HarbourVest Partners, LLC, its General Partner
    By:  

    /s/ Paula Drake

    Name:   Paula Drake
    Title:   Chief Compliance Officer, Managing Director and General Counsel
    SMRS-TOPE LLC
    By:   HVST-TOPE LLC, its Managing Member
    By:   HarbourVest Partners L.P., its Manager
    By:   HarbourVest Partners, LLC, its General Partner
    By:  

    /s/ Paula Drake

    Name:   Paula Drake
    Title:   Chief Compliance Officer, Managing Director and General Counsel

    [Schedule 13G Signature Page]

    Get the next $OMGA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OMGA

    DatePrice TargetRatingAnalyst
    11/15/2024Outperform → Mkt Perform
    Raymond James
    6/18/2024$12.00Outperform
    Raymond James
    5/25/2023$18.00 → $15.00Buy
    Jefferies
    12/8/2022$11.00Buy
    H.C. Wainwright
    9/23/2022$12.00Buy
    Chardan Capital Markets
    8/24/2021$36.00Outperform
    Wedbush
    8/24/2021$30.00Buy
    Jefferies
    8/24/2021$30.00Overweight
    Piper Sandler
    More analyst ratings

    $OMGA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Flagship Pioneering, Cambridge University Health Partners, and Milner Therapeutics Institute Announce Collaboration to Accelerate Biotech Research and Innovation

      First of its Kind Scientific Collaboration Will Engage Top Research Institutes in Cambridge, UK with Flagship Pioneering Focus on Scaling and Advancing Flagship's Breakthrough Science and Technologies through the Cambridge Life Sciences Ecosystem LONDON, Jan. 23, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced an agreement with top life science organisations Cambridge University Health Partners (CUHP) and the Milner Therapeutics Institute (MTI) to collaborate to jointly advance breakthrough scientific research and technologies. The

      1/23/25 6:00:00 AM ET
      $FHTX
      $MRNA
      $OMGA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies

      CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today announced that Angela Hwang, MBA, will join Flagship Pioneering as CEO-Partner, and Metaphore as Chief Executive Officer, effective January 1, 2025. Most recently, Hwang served as Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer. During her tenure at Pfizer, Hwang helped brin

      11/20/24 8:00:00 AM ET
      $FHTX
      $MRNA
      $OMGA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer

      Ampersand's AND™ Platform will be used to identify programmed biologics for the treatment of obesity-related targets Montai's CONECTA™ AI platform will be used to identify small molecules directed to a potential Non-Small Cell Lung Cancer-related target   Collaborations will leverage Pfizer's deep expertise in early discovery and development for cardiometabolic and cancer treatments, two priority therapeutic areas for the company CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced  Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further dev

      11/20/24 6:30:00 AM ET
      $FHTX
      $MRNA
      $OMGA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $OMGA
    Leadership Updates

    Live Leadership Updates

    See more
    • Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies

      CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today announced that Angela Hwang, MBA, will join Flagship Pioneering as CEO-Partner, and Metaphore as Chief Executive Officer, effective January 1, 2025. Most recently, Hwang served as Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer. During her tenure at Pfizer, Hwang helped brin

      11/20/24 8:00:00 AM ET
      $FHTX
      $MRNA
      $OMGA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results

      Established clinical proof-of-mechanism and validation of epigenomic controllers as potential new class of medicines from completed Phase 1 MYCHELANGELO™ I trial for c-MYC in HCC; Company exploring strategic partnership opportunities for Phase 2 development of OTX-2002Company is focusing capital resources on three prioritized programs that reflect Omega's unique value proposition to enable precision epigenomic control for potential therapeutic advantages versus existing modalitiesBoard has appointed Kaan Certel, Ph.D., as Omega's President and Chief Executive Officer, and Jennifer Nelson, Ph.D., as Chief Scientific OfficerCompany is pursuing strategic partnership opportunities to support dev

      11/14/24 4:05:00 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio

      Williams was promoted from Operating Partner at Flagship Pioneering and President at Apriori Bio Apriori Bio has made significant progress in 2024, including securing a collaboration with CEPI, assembling a world class board of directors and building out an early pipeline of prospective vaccines CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Apriori Bio, a biotechnology company aimed at providing humanity with variant-resilient protection against rapidly-evolving viruses, today announced that Craig Williams, MBA, has been promoted to CEO-Partner at Flagship Pioneering and Chief Executive Officer of Apriori.

      11/13/24 8:00:00 AM ET
      $FHTX
      $MRNA
      $OMGA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $OMGA
    Financials

    Live finance-specific insights

    See more
    • Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial

      All 8 patients treated with OTX-2002 in initial two cohorts achieved highly specific on-target genomic engagement, intended epigenetic state change and robust downregulation in expression of c-MYC, a historically ‘undruggable' target First-known clinical observation of pre-transcriptional gene modulation using a programmable epigenomic mRNA candidate Clinical proof-of-platform established; potential applicability across a broad range of diseases Company to host webcast today at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmabl

      9/26/23 7:00:11 AM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Omega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial on September 26

      CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will host a conference call and webcast to discuss preliminary clinical data from the ongoing Phase 1/2 MYCHELANGELO™ I trial of OTX-2002 on Tuesday, September 26, 2023, at 8:00 a.m. ET. The webcast will feature members of Omega's leadership team as well as a moderated discussion with Gerard Evan, Ph.D., Principal Group Leader of the Francis Crick Institute in London and Professor of Cancer Biology, King's College London. The live we

      9/25/23 4:00:32 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OMGA
    SEC Filings

    See more
    • SEC Form EFFECT filed by Omega Therapeutics Inc.

      EFFECT - Omega Therapeutics, Inc. (0001850838) (Filer)

      3/26/25 12:15:12 AM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form POS AM filed by Omega Therapeutics Inc.

      POS AM - Omega Therapeutics, Inc. (0001850838) (Filer)

      3/21/25 4:04:35 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Omega Therapeutics Inc.

      S-8 POS - Omega Therapeutics, Inc. (0001850838) (Filer)

      3/21/25 4:03:00 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OMGA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Varsalone Jeffrey T

      3 - Omega Therapeutics, Inc. (0001850838) (Issuer)

      2/4/25 9:59:03 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Mehrotra Ravi

      4 - Omega Therapeutics, Inc. (0001850838) (Issuer)

      12/5/24 4:10:05 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Mehrotra Ravi

      3 - Omega Therapeutics, Inc. (0001850838) (Issuer)

      12/5/24 4:05:05 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OMGA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Omega Therapeutics Inc. (Amendment)

      SC 13G/A - Omega Therapeutics, Inc. (0001850838) (Subject)

      2/12/24 12:03:27 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Omega Therapeutics Inc. (Amendment)

      SC 13G/A - Omega Therapeutics, Inc. (0001850838) (Subject)

      2/9/24 4:17:05 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Omega Therapeutics Inc. (Amendment)

      SC 13G/A - Omega Therapeutics, Inc. (0001850838) (Subject)

      2/9/24 9:28:31 AM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OMGA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Omega Therapeutics downgraded by Raymond James

      Raymond James downgraded Omega Therapeutics from Outperform to Mkt Perform

      11/15/24 9:11:43 AM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James initiated coverage on Omega Therapeutics with a new price target

      Raymond James initiated coverage of Omega Therapeutics with a rating of Outperform and set a new price target of $12.00

      6/18/24 7:37:53 AM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies resumed coverage on Omega Therapeutics with a new price target

      Jefferies resumed coverage of Omega Therapeutics with a rating of Buy and set a new price target of $15.00 from $18.00 previously

      5/25/23 7:51:53 AM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care